Japan’s Kyorin To License Diabetes Drug For Foreign Development
This article was originally published in PharmAsia News
Executive Summary
Kyorin Pharmaceuticals of Japan plans to license its diabetes drug currently in Phase II trials for foreign development and sale, but pursue Japanese approval on its own. KRP-104 increases insulin secretion when blood sugar levels rise as a result of eating. Kyorin expects to complete Phase II trials in the United States this summer, but license the drug to a global company to take it through Phase II trials and then to market in other countries. The drug is still in Phase I trials in Japan. (Click here for more - a subscription may be required
You may also be interested in...
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.